BELITE BIO INC - AMERICAN DEPOSITARY SHARES
53,80
10-февраля-25 15:45:00
15 мин. задержка
Акции
-3,73
-6,48%
Сегодняшний диапазон
53,16 - 57,84
ISIN
N/A
Источник
NASDAQ
- Котировки
- Графики
Новости
- Статистика
-
01 май 2024 15:15:00 Источник Nasdaq GlobeNewswire
-
Belite Bio Announces $25 Million Registered Direct Offering
25 апр 2024 18:15:29 Источник Nasdaq GlobeNewswire
-
Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
22 мар 2024 07:00:00 Источник Nasdaq GlobeNewswire
-
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
11 мар 2024 21:28:39 Источник Nasdaq GlobeNewswire
-
Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
11 мар 2024 20:27:47 Источник Nasdaq GlobeNewswire
-
06 мар 2024 07:00:01 Источник Nasdaq GlobeNewswire
-
Belite Bio to Participate in the Leerink Partners Global Biopharma Conference
04 мар 2024 07:00:00 Источник Nasdaq GlobeNewswire
-
Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
07 фев 2024 07:00:00 Источник Nasdaq GlobeNewswire
-
30 ноя 2023 07:00:00 Источник Nasdaq GlobeNewswire
-
Belite Bio to Participate in the BTIG Ophthalmology Day
20 ноя 2023 07:00:00 Источник Nasdaq GlobeNewswire
-
Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results
13 ноя 2023 19:15:47 Источник Nasdaq GlobeNewswire
-
Belite Bio to Host Webcast on November 14, 2023, to Discuss Third Quarter 2023 Financial Results
07 ноя 2023 07:00:00 Источник Nasdaq GlobeNewswire
-
06 ноя 2023 07:00:00 Источник Nasdaq GlobeNewswire
-
Belite Bio Announces Presentation at the American Academy of Ophthalmology 2023 Annual Meeting
27 окт 2023 07:00:00 Источник Nasdaq GlobeNewswire
-
Belite Bio Reports Second Quarter 2023 Operational Highlights and Financial Results
08 авг 2023 21:17:28 Источник Nasdaq GlobeNewswire
-
Belite Bio to Host Webcast on August 9, 2023 to Discuss Second Quarter 2023 Financial Results
04 авг 2023 07:00:00 Источник Nasdaq GlobeNewswire
-
Belite Bio Doses First Subject in Pivotal Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant for GA
27 июл 2023 16:00:00 Источник Nasdaq GlobeNewswire
-
30 май 2023 19:49:26 Источник Nasdaq GlobeNewswire
-
30 май 2023 15:01:00 Источник Nasdaq GlobeNewswire
-
Belite Bio Reports First-Quarter 2023 Operational Highlights and Financial Results
10 май 2023 18:58:59 Источник Nasdaq GlobeNewswire